GlassScriptPhysician profile
Robert Thaxton Wells
NPI 1437104007
$6,092.60
in general payments reported to CMS, 2019-2025
31 companies · $851 in 2025
The $851 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,060 · 2020: $834 · 2021: $1,105 · 2022: $645 · 2023: $845 · 2024: $754 · 2025: $851.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,435 · Education: $13.76.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,435.00 |
| Education | $13.76 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $3,025.41 | 2019-2025 | Skyrizi, Rinvoq, Linzess |
| Janssen Biotech, INC. | $455.07 | 2019-2025 | Tremfya, Stelara |
| Takeda Pharmaceuticals U.S.A., INC. | $441.50 | 2019-2024 | Entyvio, Eohilia |
| Pfizer INC. | $438.19 | 2019-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $429.67 | 2019-2022 | |
| Ipsen Biopharmaceuticals, INC | $226.89 | 2024-2025 | Iqirvo |
| Qol Medical, LLC | $145.52 | 2019-2025 | Sucraid, Sucraid |
| Intercept Pharmaceuticals, INC. | $111.85 | 2019-2025 | Ocaliva |
| Genzyme Corporation | $101.96 | 2023-2025 | |
| Aimmune Therapeutics, INC. | $100.13 | 2025 | Zenpep |
| Regeneron Healthcare Solutions, INC. | $76.07 | 2022-2024 | Dupixent |
| Allergan, INC. | $75.46 | 2019-2020 | |
| Laborie Medical Technologies Corp. | $45.88 | 2025 | |
| Gilead Sciences, INC. | $45.50 | 2019 | |
| Celgene Corporation | $44.87 | 2021-2023 | Zeposia |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ironwood Pharmaceuticals, INC | $37.05 | 2019-2020 | |
| Amag Pharmaceuticals, INC. | $28.90 | 2022 | |
| Medtronic, INC. | $28.72 | 2023 | Interstim |
| Braintree Laboratories, INC. | $26.10 | 2020-2023 | Sutab, Suflave |
| Merck Sharp & Dohme LLC | $24.21 | 2021 | |
| Cook Medical LLC | $21.39 | 2023 | Hemospray |
| Boston Scientific Corporation | $19.93 | 2019 | |
| Celltrion USA INC. | $19.33 | 2025 | Vegzelma |
| Lilly USA, LLC | $17.91 | 2025 | Omvoh |
| Amgen INC. | $17.71 | 2023 | Avsola, Amjevita |
| Sandoz INC. | $17.59 | 2024 | Hyrimoz |
| Micro-Tech Endoscopy USA, INC. | $15.80 | 2024 | Eyemax |
| Alnylam Pharmaceuticals INC. | $15.69 | 2025 | Givlaari |
| Madrigal Pharmaceuticals | $14.73 | 2024 | Resmetirom |
| Olympus America INC. | $12.18 | 2019 | |
| Endo Pharmaceuticals INC. | $11.39 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Wells listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.